The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Company wins court ruling to continue development of Michigan factory serving EV industry
Sam Rubin, beloved LA entertainment anchor and interviewer, dies at 64
Revealed: England's 'postcode lottery' of maternity care laid bare in interactive map and table
Families still looking for missing loved ones after devastating Afghanistan floods killed scores
Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
20 of the best villas in Portugal (from £27 per person a night)
Dr. Cyril Wecht, famed forensic pathologist who argued more than 1 shooter killed JFK, dies at 93
Severe weather: US South hit again after one of the most active tornado periods in history
'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
Indonesian police raid drug lab in Bali villa
Four people killed in a house explosion in southwestern Missouri
Palestinian band escapes horrors of war but members' futures remain uncertain